ATLANTA, March 11, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX ® (bimekizumab) versus SKYRIZI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results